# A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities

> **NCT03410927** · PHASE1 · TERMINATED · sponsor: **Taiho Oncology, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Advanced Solid Tumors With HER2 Abnormalities
- Advanced Solid Tumors With HER3 Abnormalities

## Interventions

- **DRUG:** TAS0728

## Key facts

- **NCT ID:** NCT03410927
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-06
- **Primary completion:** 2022-06-09
- **Final completion:** 2022-06-09
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** The study was stopped due to unacceptable toxicity during the dose-escalation portion (Phase 1) of the study and did not progress to Phase 2
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03410927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03410927, "A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03410927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*